Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Calcifediol Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 8/20 | 0.82 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | SREBF1 | P36956 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.82 |
| ▸ | PGR | P06401 | 2/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
| ▸ | CDC25A | P30304 | 1/20 | 0.82 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.82 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.82 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.82 |
| ▸ | DRD3 | P35462 | 1/20 | 0.82 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcifediol Anhydrous SCHEMBL15263245 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL9083623 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL12633974 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL5614028 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL24102681 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL15168893 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL24051907 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL15168894 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL24571935 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL22403256 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2070 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4062917-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-12-03 | — | — | EP | claimed |
| EP-4647447-A2 | BINDING PARTNERS SPECIFIC FOR VITAMIN D EPIMERS | Siemens Healthcare Diagnostics, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| WO-2025129271-A1 | LIPID DELIVERY VEHICLE | THE UNIVERSITY OF QUEENSLAND (AU) | 2025-06-26 | — | — | WO | claimed |
| WO-2025122686-A1 | COMPOSITIONS AND METHODS FOR TREATING OBESITY | YALE UNIVERSITY (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025101030-A1 | NANOSTRUCTURE COMPRISING CYCLODEXTRIN-DERIVED POLYMER MATERIAL AND GUEST MATERIAL, AND USE THEREOF | 한국과학기술연구원 | 2025-05-15 | — | — | WO | claimed |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-01-07 | — | — | US | claimed |
| US-20240374604-A1 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2024-11-14 | — | — | US | claimed |
| EP-3711058-B1 | METHOD FOR DETECTING ABNORMAL VALUES OF A BIOMARKER | UNIV PARIS CITE (FR) | 2024-10-09 | — | — | EP | claimed |
| EP-1890679-A2 | STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF | Foamix Ltd. (IL) | 2008-02-27 | — | — | EP | claimed |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-05 | — | — | US | claimed |
| WO-2007012977-A2 | STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF | FOAMIX LTD (US) | 2007-02-01 | — | — | WO | claimed |
| WO-2006096555-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | WOMEN AND INFANTS HOSPITAL OF RI, INC. (US) | 2006-09-14 | — | — | WO | claimed |
| US-20060018937-A1 | Steroid kit and foamable composition and uses thereof | FOAMIX LTD. | 2006-01-26 | — | — | US | claimed |
| US-20050025807-A1 | Cured porous calcium phosphate material and uses thereof | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY | 2005-02-03 | — | — | US | claimed |
| WO-2004098612-A2 | CALCITRIOL ANALOGS OF USES THEREOF | AB SCIENCE (FR) | 2004-11-18 | — | — | WO | claimed |
| US-6034075-A | ADMINISTERIN CALCIUM | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2000-03-07 | — | — | US | claimed |
| EP-0660718-B1 | METHOD OF TREATING PREMENSTRUAL SYNDROME SYMPTOMATOLOGY WITH VITAMIN D OR VITAMIN D AND CALCIUM | THYS JACOBS SUSAN (US) | 1999-12-08 | — | — | EP | claimed |
| US-5443850-A | Method for treating symptoms associated with vascular headaches by administering a combination of calcium and vitamin D | THYS-JACOBS SUSAN (US) | 1995-08-22 | — | — | US | claimed |